Vitrolife AB (publ) has today received market approval for the time-lapse incubator EmbryoScope+ in China, the world's largest market measured in terms of number of IVF treatments.
EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for fifteen patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. In 2018, Vitrolife received market approval in China for the EmbryoScope time-lapse system, with capacity for six patients. "We are delighted to receive market approval in China for EmbryoScope+, whose high capacity fits well with the large Chinese clinics," says Thomas Axelsson, CEO of Vitrolife.
March 15, 2019
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on March 15, 2019.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.